

RETINA PIPELINE 2023

A VIEW INTO ONGOING INNOVATION

WET AMD




PETER K. KAISER, MD
Medical Advisor, *Retina Today*;
Cole Eye Institute, Cleveland
Clinic, Cleveland, OH



MARIELLE MAHAN, MD
Ophthalmology Resident, MedStar Georgetown
University Hospital/Washington Hospital Center,
Washington, D.C.



LEGEND



TIE2 Activation Pathways

- faricimab (Genentech/Roche) **FDA-APPROVED**
- BI 836880 (Boehringer Ingelheim)
- RO-101 (RevOpsi)
- ASKG-712 (AffaMed, AskGene Pharma)



Gene Therapy

- RGX-314 (REGENXBIO, AbbVie)
- ADVM-022 (Adverum Biotechnologies)
- 4D-150 (4D Molecular Therapeutics)

Integrin Pathways

- PAN risuteganib (Allegro Ophthalmics/Senju Pharma)
- THR-687 (Oxurion)
- volociximab (Iveric Bio)
- OTT116 (OcuTerra Therapeutics)
- AG-73305 (Allgenesis Biotherapeutics)
- AXT107 (AsclepiX Therapeutics)

Other Pathways

- CVX-51401 (CavtheRx) – Caveolin Modulator
- APX3330 (Ocuphire Pharma, Inc.) – Ref-1 Inhibitor
- AR-13503 (Aerie Pharmaceuticals/Alcon) – Rho Kinase (ROCK) Inhibitor
- EXN407 (Exonate) – SRPK1 Inhibitor
- aganirsen (Gene Signal) – Inhibition of Insulin Receptor Substrate 1 (IRS-1)
- PL9654 (Palatin) – Melanocortin Receptor Agonist

Tyrosine Kinase inhibitor (TKi) Pathways

- OTX-TKI/axitinib (Ocular Therapeutix)
- KPI-287 (Kala Pharmaceuticals)
- GB-102/sunitinib (Graybug Vision)
- PAN 90806/CP-547,632 (PanOptica)
- CLS-AX/axitinib (Clearside Biomedical)
- EYP-1901/vorolanib (EyePoint Pharmaceuticals)

Extracellular VEGF Pathways

	VEGF			
	PIGF	D	C	B
biosimilars	pegaptanib (Bausch + Lomb) FDA-APPROVED			
	ranibizumab (Genentech/Roche) FDA-APPROVED			
	Xlucane (Bausch + Lomb)			
	ranibizumab-nuna (Samsung/Biogen) FDA-APPROVED			
	PF582 (Pfizer)			
	ranibizumab-eqrn (Formycon/Coherus) FDA-APPROVED			
	ranibizumab-razumab (Intas)			
	SJP-0133 (Senju Pharma)			
	LUBT010 (Lupin)			
	Ongavia (Teva Pharmaceuticals)			
biosimilars	BCD100 (BIOCND/Qilu)			
	bevacizumab OFF-LABEL			
	bevacizumab-vikg (Outlook Therapeutics)			
	HLX04-0 (Hengenix Biotech)			
biosimilars	TAB014 (Zhaoke Ophthalmology)			
	brolucizumab (Novartis) FDA-APPROVED			
	abicipar pegol (Molecular Partners AG)			
	KNP-301 (Kanaph Therapeutics)			
	tarcocimab tedromer (Kodiak Sciences)			
	aflibercept (Regeneron) FDA-APPROVED			
	ALT-L9 (Alteogen)			
	M710 (Mylan/Momentra)			
	SB15 (Samsung)			
	CHS-2020 (Coherus)			
biosimilars	SOK583A1 (Sandoz/Novartis)			
	ABP 938 (Amgen)			
	conbercept (Kanghong Biotech) CDE-APPROVED			
	OPT-302 (Opthea)			

If you would like to submit an addition for next year's poster, please email Peter K. Kaiser, MD, at pkkaiser@gmail.com and Cara Deming at cdeming@bmctoday.com.

View Interactive
Version Online



Content guidance and source: Peter K. Kaiser, MD; Marielle Mahan, MD | *Editorially independent content supported by advertising from Genentech

THE
WINDOW
TO CHANGE

STEP INTO THE FUTURE OF OPHTHALMOLOGY

Genentech
A Member of the Roche Group